目的 探究心脉隆注射液联合左卡尼汀注射液治疗慢性心力衰竭的临床疗效。方法 选取2014年1月—2016年10月衡水市第四人民医院收治的心力衰竭患者200例作为研究对象，根据患者入院顺序分为对照组和治疗组，每组各100例。对照组静脉滴注左卡尼汀注射液，2 g加入到0.9%氯化钠注射液50 mL中，滴速为20～40滴/min，1次/d。治疗组在对照组治疗基础上静脉滴注心脉隆注射液，5 mg/kg加入到0.9%氯化钠注射液250 mL中，滴速为20～40滴/min，2次/d。所有患者均连续治疗14 d。观察两组的临床疗效，比较两组的心功能指标、血清学指标和6 min步行距离。结果 治疗后，对照组和治疗组的总有效率分别为82.00%、95.00%，两组比较差异有统计学意义（P<0.05）。治疗后，两组左室射血分数（LVEE）和心指数（CI）均明显升高，左心室舒张末期内径（LVEDD）、左心室收缩末期容积（LVESV）、左心室收缩末期内径（LVESD）均明显下降，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些观察指标的改善程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清N末端脑钠肽元（NT-proBNP）、血管紧张素Ⅱ（Ang Ⅱ）、血浆醛固酮（ALD）、血浆心钠素（ANP）水平均显著下降，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些观察指标明显低于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组6 min步行距离显著增加，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组6 min步行距离明显长于对照组，两组比较差异具有统计学意义（P<0.05）。结论 心脉隆注射液联合左卡尼汀注射液治疗慢性心力衰竭具有较好的临床疗效，可改善心功能，调节血清学指标，增加6 min步行距离，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Xinmailong Injection combined with Levocarnitine Injection in treatment of chronic heart failure. Methods Patients (100 cases) with chronic heart failure in the No. 4 People's Hospital of Hengshui from January 2014 to October 2016 were divided into control and treatment groups according to order of admission, and each group had 100 cases. Patients in the control group were iv administered with Levocarnitine Injection, 2 g added into normal saline 50 mL, the drop speed was 20-40 drops/min, once daily. Patients in the treatment group were iv administered with Xinmailong Injection on the basis of the control group, 5 mg/kg added into normal saline 250 mL, the drop speed was 20-40 drops/min, twice daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and cardiac function indexes, serological indexes, and 6 min walking distance in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.00% and 95.00%, respectively, and there was difference between two groups (P < 0.05). After treatment, LVEE and CI in two groups were significantly increased, but LVEDD, LVESV, and LVESD in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of NT-proBNP, Ang Ⅱ, ALD, and ANP in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the 6 min walking distance in two groups were significantly increased, and the difference was significant in the same group (P < 0.05). And the observational indexes in the treatment group were longer than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Xinmailong Injection combined with Levocarnitine Injection has clinical curative effect in treatment of chronic heart failure, can improve cardiac function, regulate serological index, and increase 6 min walking distance, which has a certain clinical application value.

衡水市科技计划项目（2016014041Z）